Top
image credit: Flickr

Medtronic touts new targeted drug delivery study results

April 8, 2019

Targeted drug delivery and conventional medical management have shown to have a reduction in healthcare use and costs for cancer patients in comparison to conventional medical management alone, according to a new study from Medtronic.

The study found that there were significant cost savings to payers and fewer inpatient visits with shorter inpatient stays. It also showed that there were fewer emergency department visits for people who used targeted drug delivery (TDD) and conventional medical management (CMM).

Read More on Mass Device